MoonLake Immunotherapeutics

MLTX

Biotech

Health Care

Pharma

Country

CH

Industry

Health Care

Market Cap

Small Cap

Num. Employees

20

IPO Date

Oct 20, 2020

Create Alert

MLTX

Country

CH

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 20 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.